Smog Check Network Announces Statewide Launch of Its Online Platform Across California
San Francisco, California--(Newsfile Corp. - July 8, 2025) - Smog Check Network is pleased to announce the statewide launch of its online platform. Available at www.smogcheck.net, the digital platform enables California smog check stations to offer their services online, accept online payments, manage appointments, and maintain digital paperwork. This milestone marks a major step in modernizing California's vehicle emissions testing process.
By allowing drivers to compare certified smog check stations, view prices upfront and book and pay online, Smog Check Network eliminates the guesswork and annoyance historically associated with smog testing, making the entire process seamless, efficient, and transparent.
"For decades, getting a smog check in California has meant calling around to compare prices, driving from one location to another, and dealing with long wait times and uncertain costs," said Kayvan Najafzadeh, CEO and co-founder of Smog Check Network. "We created this platform to bring the smog check industry into the digital age, making the process easier for consumers while giving shops the tools they need to thrive in a competitive online-first environment."
Independent smog check stations across California can now claim their profiles, showcase services, receive direct online bookings, manage scheduling, and process digital check-ins through their Smog Check Network listings. The system reduces administrative overhead while improving shop efficiency, customer preparedness, and service throughput.
The online platform also includes digital paperwork and recordkeeping functionality — a first for many participating shops — ensuring stations stay organized and compliant with state regulations.
Smog Check Network's new tools help shops keep pace with growing demand while enhancing the testing experience for everyone involved.
Businesses that manage fleets, such as dealerships and rideshare operators, can also take advantage of Smog Check Network's enterprise features, including bulk scheduling, centralized invoicing, and real-time vehicle tracking.
Looking ahead, the company is already developing mobile-first check-in tools, SMS reminders, real-time wait tracking, and expanded ride share and car rental inspections as well as integrations with municipal and corporate fleets. Smog Check Network remains committed to simplifying vehicle care and emissions compliance for all Californians.
About Smog Check Network
Smog Check Network is an online platform designed to make vehicle emissions testing in California easier and more transparent for both consumers and businesses. By enabling drivers to view pricing, compare certified smog check stations, book appointments, and pay online, the platform brings much-needed modernization to the smog check process. For smog check shops, Smog Check Network provides marketing visibility, digital tools, and a new stream of high-quality customers.
To schedule your smog check or to learn more, visit www.smogcheck.net.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Bayer Gets FDA Nod for Label Expansion of Kerendia in Heart Failure
Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The regulatory body approved finerenone for the treatment of adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40%. The approval of finerenone by the FDA for this new indication is based on the positive results of the late-stage FINEARTS-HF study, which is part of the ongoing MOONRAKER program — one of the largest phase III clinical trial programs to date in heart failure. Year to date, shares of Bayer have rallied 64.1% compared with the industry 's growth of 1.8%. More on Bayer's Kerendia Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block harmful effects of MR overactivation. MR overactivation contributes to chronic kidney disease (CKD) progression and cardiovascular damage caused by metabolic, hemodynamic, or inflammatory and fibrotic factors. Finerenone is marketed as Kerendia (Firialta in some countries) and is already approved for the treatment of adult patients with CKD associated with type 2 diabetes (T2D) in more than 95 countries worldwide, including China, Europe, Japan and the United States. With the latest FDA approval, Kerendia is the only non-steroidal MR antagonist approved in the United States for CKD associated with T2D and for HF with LVEF of ≥40%. Please note the FDA granted Priority Review designation to the supplemental new drug application seeking approval for finerenone for the treatment of adult patients with HF with an LVEF of ≥40%. Per estimates, approximately 3.7 million people in the United States live with HF with an LVEF of ≥40%, which accounts for more than 500,000 hospitalizations per year. Data from the FINEARTS-HF study showed that finerenone achieved a statistically significant and clinically meaningful reduction of the composite of cardiovascular death and total (first and recurrent) HF events, defined as hospitalizations for HF or urgent HF visits. These benefits were demonstrated regardless of background therapy, comorbidities, or hospitalization status. Finerenone has also been submitted for marketing authorization in HF with an LVEF of ≥40% in China, the EU and Japan. BAYRY's Efforts to Strengthen Pharma Business Bayer's new products, such as Nubeqa and Kerendia, continue to maintain their impressive momentum in the Pharmaceutical division and offset the negative impact of a decline in Xarelto sales. Labels of these key drugs should boost its top-line growth. Last month, the FDA also expanded Nubeqa's label for a third indication for patients with advanced prostate cancer. The successful development of additional drugs is imperative for Bayer amid multiple challenges. BAYRY expects to launch two new drugs — elinzanetant, a hormone-free treatment for menopause symptoms, and acoramidis, a drug for the treatment of a certain type of heart disease. Elinzanetant was recently approved in the UK for the treatment of moderate to severe vasomotor symptoms (VMS or hot flashes) associated with menopause under the brand name Lynkuet. The company also aims to strengthen its pharmaceutical pipeline. In 2021, Bayer acquired clinical-stage biopharmaceutical company Vividion Therapeutics to expand its presence in precision small-molecule therapeutics, primarily in oncology and immunology. BAYRY has expanded its pipeline in new modalities of cell therapy through the acquisition of BlueRock, and in gene therapy, through the AskBio buyout. Bayer's Zacks Rank & Other Key Picks BAYRY currently carries a Zacks Rank #1 (Strong). A couple of other top-ranked stocks in the large-cap pharma sector are Novartis NVS and Johnson & Johnson JNJ, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.78 to $8.92 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.27 during the said timeframe. The stock has risen 27.3% so far this year. J&J's EPS estimate for 2025 has risen from $10.60 to $10.64 over the past 60 days, while that for 2026 has increased from $10.98 to $11.07 over the same timeframe. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
Globe and Mail
27 minutes ago
- Globe and Mail
3 Must-Buy Technology Bigwigs With Solid Earnings Estimate Revisions
Wall Street has maintained its northward journey after an impressive bull run of the past two and a half years. The technology sector, driven by the astonishing adoption of generative artificial intelligence (AI) across the world, was the primary driver of this rally. The sector suffered some hurdles in the first half of 2025 but regained strong momentum in the past two months. We have selected three technology bigwigs that witnessed solid earnings estimate revisions in the last 60 days. This indicates that market participants are expecting these companies to do good business in the near future. Moreover, each of our picks currently sports a Zacks Rank #1 (Strong Buy), reflecting strong price upside potential in the near future. You can see the complete list of today's Zacks #1 Rank stocks here. These stocks are: Dell Technologies Inc. DELL, Jabil Inc. JBL and Credo Technology Group Holding Ltd. CRDO. Dell Technologies Inc. Dell Technologies has been benefiting from strong demand for AI servers driven by ongoing digital transformation and heightened interest in generative AI applications. In the last reported quarter, DELL secured $12.1 billion in AI server orders, surpassing shipments and building a strong backlog. DELL's PowerEdge XE9680L AI-optimized server is in high demand. Strong enterprise demand for AI-optimized servers is aiding the company. A robust partner base, which includes the likes of NVIDIA, Google and Microsoft has been a major growth driver. DELL is expanding its cloud services through its infrastructure solutions and rich partner base that provides essential hardware and services that support cloud environments. Through its APEX platform, DELL provides multi-cloud solutions and advanced AI infrastructure, which have become key highlights of its offerings. Dell Technologies has an expected revenue and earnings growth rate of 8.7% and 16%, respectively, for the current year (ending January 2026). The Zacks Consensus Estimate for current-year earnings has improved 0.1% over the last 30 days. Jabil Inc. Jabil has been benefiting immensely from healthy momentum in capital equipment, AI-powered data center infrastructure, cloud, and digital commerce business verticals. Its focus on end-market and product diversification is a key catalyst. Jabil's target that 'no product or product family should be greater than 5% operating income or cash flows in any fiscal year' is commendable. JBL's high free cash flow indicates efficient financial management practices, optimum utilization of assets, and improved operational efficiency. Massive application of generative AI is set to drastically increase the efficiency of JBL's automated optical inspection machines for the automation industry. A large-scale portfolio of business sectors offers JBL a high degree of resiliency during times of macroeconomic and geopolitical disruption. Jabil has an expected revenue and earnings growth rate of 5.8% and 17.8%, respectively, for next year (ending August 2026). The Zacks Consensus Estimate for next-year earnings has improved 8.4% over the last 30 days. Credo Technology Group Holding Ltd. Credo Technology is a provider of high-performance serial connectivity solutions for the hyperscale datacenter, 5G carrier, enterprise networking, artificial intelligence and high-performance computing markets. CRDO's main business is its Active Electrical Cables (AEC) product line. AEC is gaining traction owing to its increasing adoption in the data center market. The demand for AECs is increasing as ZeroFlap AECs offer more than 100 times improved reliability than laser-based optical solutions. This made AECs an increasingly attractive option for data center applications. With the demonstration of PCIe Gen6 AECs and increasing hyperscaler interest, this product line is expected to remain a growth engine. Strength in the optical business, particularly Optical Digital Signal Processors (DSPs), is another key catalyst. CRDO expects an expansion of customer diversity across lane rates, port speeds and applications to accelerate revenue growth going forward. CRDO announced that it achieved a key 800-gig transceiver DSP design win and unveiled ultra-low-power 100-gig per lane optical DSPs built on 5-nanometer technology. CRDO expects its 3-nanometer 200-gig-per-lane optical DSP to boost the industry's transition to 200-gig lane speeds. Supplementing these businesses is CRDO's PCIe retimers and Ethernet retimers business. This particular product line continues to witness customer interest, especially for scale-out networks in AI servers. CRDO highlighted that the retimer business delivered 'robust' performance driven by 50 gig and 100 gig per lane Ethernet solutions. This growing demand underscores the increasing importance of high-performance solutions in the rapidly expanding AI server market. Shift to 100 gig per lane solutions and higher demand for system-level expertise and software capabilities for dealing with AI-optimized architectures bode well for CRDO's retimer business. Credo Technology has an expected revenue and earnings growth rate of 85.8% and more than 100%, respectively, for the current year (ending April 2026). The Zacks Consensus Estimate for current-year earnings has improved 37% in the last 60 days. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dell Technologies Inc. (DELL): Free Stock Analysis Report Jabil, Inc. (JBL): Free Stock Analysis Report Credo Technology Group Holding Ltd. (CRDO): Free Stock Analysis Report
Globe and Mail
42 minutes ago
- Globe and Mail
CRWV Stock Jumps 209% in 3 Months: Hold Steady or Make an Exit?
CoreWeave, Inc. CRWV stock has appreciated 208.5% in the past three months and closed last session at $125.84, jumping more than threefold from its initial opening price of $39 on March 28, 2025. With its GPU-based cloud solutions tailored for AI workloads, CRWV is well-positioned to gain from the AI infrastructure boom. Strategic partnerships with major players like OpenAI and NVIDIA bode well along with massive $259 billion revenue backlog. The company has outpaced its peers like Nebius Group N.V. NBIS, Microsoft MSFT and Amazon AMZN. Nebius, Microsoft and Amazon shares have gained 107.6%, 30.4% and 25.3%, respectively, in the same time frame. Price Performance However, the stock has declined sharply post its announcement of $9 billion takeover of Core Scientific. Since the announcement on July 7, CRWV has lost 21%. This recent slump is bound to raise an inevitable question: Is it still worth holding or making an exit is the smarter choice? Let's break down the key advantages and potential risks to help determine the smartest move for your portfolio. CRWV Faces Headwinds Apart from scrutiny surrounding the company's latest acquisition bid, it also faces other headwinds. CRWV's aggressive capital deployment strategy is a key concern. CRWV expects capex to be between $20 billion and $23 billion for 2025 due to accelerated investment in the platform to meet customer demand. Higher capex can be a concern if revenues do not keep up the required pace to sustain such high capital intensity, especially in a macro environment where AI demand cycles could fluctuate due to competitive pricing and regulatory changes. The company uses a success-based model, entering capex programs only after securing multi-year customer contracts that cover investment costs within the contract terms, helping it to sensibly scale the debt structure. High capex, even with a success-based model, exposes CoreWeave to execution risks if contract revenue does not materialize on time. CoreWeave's aggressive data center buildout is being funded in part by debt. In the last earnings call, management acknowledged a surge in interest expenses. In the first quarter, interest expense came in at $264 million, topping expectations. This was attributed to changes in vendor payment terms. The company now guides interest expense to remain elevated, at $260-$300 million in the current quarter. Higher interest expenses can exert pressure on the adjusted net income and potentially affect free cash flow generation. Owing to high interest expenses, CoreWeave's adjusted net loss increased to $150 million in the first quarter, compared to $24 million in prior year quarter, despite achieving 420% revenue growth. CRWV also anticipates stock-based compensation to remain slightly higher in 2025 for the grants issued pertaining to the IPO. CoreWeave faces tough competition in the AI cloud infrastructure space, which boasts behemoths like Amazon and Microsoft and other players like Nebius. Amazon Web Services and Microsoft's Azure cloud platform together dominate more than half of the cloud infrastructure services market. Nebius is another upcoming player with hyper revenue growth of 385% in the last reported quarter. Customer concentration is another major risk. CoreWeave's 77% of total revenues in 2024 came from the top two customers. This is a serious concern, especially if the client migrates, the revenue impact could be material. Apart from this evolving trade policy, macro uncertainty and volatility remain additional headwinds. Given these aforementioned headwinds, there has been a massive downward revision for CRWV's earnings estimates in the past 60 days. Image Source: Zacks Investment Research Lofty Valuation for CRWV Valuation-wise, CoreWeave seems overvalued, as suggested by the Value Score of F. In terms of Price/Book, CRWV shares are trading at 31.69X, way higher than the Internet Software industry's ratio of 6.54X, but it could mean more risk than opportunity. The recent rally suggests that a lot of future growth may already be priced in. Image Source: Zacks Investment Research Conclusion: Offload CRWV Stock CRWV currently carries a Zacks Rank #4 (Sell). For investors who have ridden the recent wave, it may be wise to lower exposure and lock in gains, especially given the high expectations already factored into the stock price. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Nebius Group N.V. (NBIS): Free Stock Analysis Report CoreWeave Inc. (CRWV): Free Stock Analysis Report
